GLP-1 receptor agonist exenatide restores atypical antipsychotic clozapine treatment-associated glucose dysregulation and damage of pancreatic islet beta cells in mice  by Hsu, Brend Ray-Sea & Fu, Shin-Huei
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Background  and  aims:  The  aim  of  this  study  was  to investigate  the  effect  of  a glucagon-like  peptide-1
receptor  agonist  (GLP-1RA),  exenatide,  on clozapine-associated  glucose  dysregulation  in  mice.
Materials  and methods:  We  randomly  separated  B6  male  mice  into  four  groups  (A to  D).  Mice  in  groups  C
and  D received  a daily  oral dose  of  13.5  mg/kg  body  weight  of  clozapine  for 4  months.  Mice  in  groups  B
and  D  received  1 g of exenatide  daily. The  body  weight  and  blood  glucose  before  and  2  h  after  clozapine
treatment  were measured  twice  a week.  Intraperitoneal  glucose  tolerance  test (IPGTT)  scores  and  the
amount  of daily  food  intake  were  recorded.  The  pancreases  of  the  mice  were  removed  for  insulin  content
(PIC)  measurement  and  histological  examination  after  sacriﬁce.
Results:  The  mean  non-fasting  blood  glucose  levels  were  not  different,  and  the mean  changes  in  blood
glucose  2 h  after  oral  clozapine  were 0 ± 4, −40 ±  2, 25  ± 3, and  −39  ±  2, in  groups  A  to  D, respectively.
There was  no signiﬁcant  difference  in daily  calorie  intake or area  under  the  curve  of  IPGTT  among  the
four  groups.  At sacriﬁce,  the  PIC of  mice  treated  with  clozapine  was  signiﬁcantly  lower  than  that  of  thexenatide (PubChem CID: 16158469)
lozapine (PubChem CID: 2818)
control  mice,  however  the  PIC  was  completely  restored  in  the  mice  treated  with  exenatide.  Histological
examination  of  the pancreas  revealed  that  exenatide  treatment  reversed  the  clozapine-induced  apoptosis
of islet  cells.
Conclusion:  Our  results  provide  preclinical  evidence  of a pharmaceutical  role  of  GLP-1RA  in managing
glucose  dysregulation  in  schizophrenic  patients  under  long-term  atypical  antipsychotic  treatments.
© 2016  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC. Introduction
Atypical or second-generation antipsychotic medications are
hought to be more effective with fewer extrapyramidal side effects
han conventional antipsychotic in the treatment of schizophrenia
nd other psychiatric disorders. However, patients taking cloza-
ine, olanzapine and quetiapine have been reported to have a
igniﬁcantly increased risk of developing diabetes than those not
aking antipsychotics and those taking conventional antipsychotics
uch as haloperidol [1–4]. Although it is widely assumed that the
evelopment of diabetes in psychiatric patients taking atypical
ntipsychotics is caused by peripheral insulin resistance follow-
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ent of Internal Medicine, Chang-Gung Medical Center and Chang-Gung University,
5, Fushin Street, Kweishan District, Taoyuan, Taiwan.
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214-7500/© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access
c-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ing excessive weight gain, the mechanism of action by which
atypical antipsychotics induce glucose dysregulation has yet to
be elucidated [5,6]. In rodent models, the short-term adminis-
tration of clozapine and quetiapine has been shown to cause
acute and reversible derangement of glucose metabolism via sup-
pressing glucagon-like peptide-1 (GLP-1) and elevating glucagon
secretion which subsequently increases hepatic gluconeogenesis
[7,8]. Whether anti-diabetic drugs are effective in reversing the
adverse effects of atypical antipsychotics on glucose metabolism
dysregulation is largely unknown. Lifestyle interventions are the
fundamental strategy to prevent the onset of diabetes and man-
age hyperglycemia in high-risk subjects such as those with obesity,
impaired glucose tolerance and metabolic syndrome. However,
lifestyle interventions per se are not adequate to prevent the
development of diabetes in schizophrenic patients who are taking
atypical antipsychotics [9]. Moreover, metformin, the corner-stone
drug in the management of type 2 diabetes, can only partially
reverse derangements of atypical antipsychotic-associated glu-
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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Fig. 1. Effect of exenatide on clozapine treatment-associated glucose metabolism derangement. We randomly separated healthy B6 male mice into four groups (A to D). The
mice  in groups C and D were given a daily oral dose of 13.5 mg/kg body weight of clozapine in a volume of 250 L for 4 months, while those in groups A and B received the
same  volume of distilled water. The mice in groups B and D received a daily subcutaneous injection of 1 g of exenatide 1 h before the oral administration of clozapine or the
vehicle.  Non-fasting random blood glucose levels at 8:00-9:00 a.m. (solid markers) and blood glucose levels 2 h after the administration of clozapine or the vehicle (blank
markers) were recorded twice a week.
Fig. 2. Effect of clozapine on the proliferation of pancreatic islet cells. Immunohistochemical analysis of the pancreatic islet cells 2 weeks after the start of the experiment
revealed that the administration of clozapine resulted in a decrease in Ki67 positively-stained nuclei (arrows in group C), and that the administration of exenatide resulted
in  an increase in Ki67 positively-stained nuclei (arrows in groups B and D).
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aig. 3. Effect of clozapine on the apoptosis of pancreatic islet cells. Immunohistoc
evealed that the administration of clozapine resulted in an increase in apoptotic n
f  the control mice (group A) or the mice that received exenatide (groups B and D).
ose metabolism [10]. Therefore, new pharmaceutical strategies
re needed to manage glucose dysregulation in patients who are
aking atypical antipsychotics. GLP-1 receptor agonists have been
hown to inhibit apoptosis and enhance the proliferation of pancre-
tic islet beta cells and to suppress glucagon secretion, along with
ther beta cell protective functions such as weight reduction and
nti-inﬂammatory properties [11,12]. However there is a paucity of
reclinical evidence for the beneﬁcial effect of GLP-1 receptor ago-
ists on atypical antipsychotic-associated glucose dysregulation. In
his study, we investigated the effect of administering clozapine for
 months on glucose variability and pancreatic islet beta cell mass,
nd studied the effect of a GLP-1 receptor agonist, exenatide, on
erangements of clozapine-associated glucose metabolism.
. Materials and methods
.1. Animals
Male C57BL/6 mice (8–12 weeks old) were obtained from a local
reeder, and three to ﬁve mice were housed in each cage and fed
elleted food and tap water ad libitum. The animal room had an
utomatic light cycle with 12 h of light and 12 h of dark. The animals
ere treated humanely in accordance with the laboratory animal
uidelines of Chang-Gung Memorial Hospital.
.2. Experimental designs
We  randomly separated healthy B6 male mice into four groups
A–D). Mice in groups C and D were given a daily oral dose of
3.5 mg/kg body weight of clozapine in a volume of 250 L for 4
onths, while mice in the groups A and B received the same vol-
me  of distilled water. Mice in groups B and D received a daily
ubcutaneous injection of 1 g of exenatide 1 h before the oral
dministration of clozapine or the vehicle. Body weight and non-
asting random blood glucose level at 8:00–9:00 a.m. (basal BG)
nd blood glucose 2 h after the administration of clozapine or thecal analysis of the pancreatic islet cells 2 weeks after the start of the experiment
arrows in group C). No apoptotic nuclei were observed in the pancreatic islet cells
vehicle (2-h BG) were recorded twice a week. The acute effect of
clozapine on glucose derangement (BG) was  expressed as the dif-
ference in subtracting basal BG from 2-h BG on the same day. The
long-term change in body weight (BW) was  calculated as the dif-
ference in average body weight between the ﬁrst week and the
sixteenth week. Bilateral gastrocnemius and peri-renal fat pads of
all mice were removed after sacriﬁce and weighed.
2.3. Daily food intake
At 2 and 14 weeks of the experiment, six mice from each group
were placed separately in metabolic cages and the amount of
daily chow intake was measured for 3 consecutive days. The aver-
age daily chow intake over the 3 days was  used in analysis and
expressed as g/kg body weight/day.
2.4. Islet function according to the intraperitoneal glucose
tolerance test
At 14 weeks, each mouse in each group received an intraperi-
toneal glucose tolerance test (IPGTT) using 1.5 g/kg of body
weight of dextrose solution. The area under the curve (AUC,
minute × mg/dL) was determined by the whole blood glucose con-
centration measured before and 30, 60, 90 and 120 min  after the
dextrose injection.
2.5. Quantitation of serum levels of glucagon and chemokines
At the end of 14 weeks, sera were collected at basal (before exe-
natide) and 2 h after clozapine administration to measure glucagon
concentrations using a Glucagon EIA kit from Phoenix Pharma-
ceutical Inc. (Burlingame, CA, USA). The basal sera samples were
also subjected to quantitative analysis for chemokines including
GM-CSF, RANTES, MCP-1, MCP-3, MIP-1 and MIP-1 using a Flow-
Cytomix multiplex kit (eBioscience, San Diego, CA, USA).
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Table  1
Effect of GLP-1 receptor agonist, exenatide, on the clozapine-induced acute derangement of glucose metabolism. a,b,c,dp < 0.001 when the two indicated means were compared.
n Clozapine GLP-1RA Mean of average BG Mean of non-fasted random BG (mg/dL) IPGTT (AUC, min × mg/dL)
A 15 − − 0 ± 4a,b,c 135 ± 3 21208 ± 845
B  15 − + −40 ± 2a 125 ± 2 19484 ± 687
C  15 + − 25 ± 3b,d 122 ± 1 21440 ± 848
D  15 + + −39 ± 2c,d 127 ± 2 20568 ± 645
Table 2
Effect of GLP-1 receptor agonist on the clozapine-induced changes in body weight, daily amount of chow intake, and the mass of muscle and peri-renal fat pad. a,jp < 0.05,
b,c,d,gp < 0.01 e,f,hp < 0.005, d,f,ip < 0.001 when the two indicated means were analyzed using unpaired t-test.
n Clozapine GLP-1RA BW (g) Amount of chow intake (g/kg BW/day) Gastrocnemius (g) Peri-renal fat pad (g)
A 12 − − 7.11 ± 1.11a,b,c 12.4 ± 0.6 0.385 ± 0.014d,e,f 0.451 ± 0.010g,h,i
a
 0.7 0.354 ± 0.010d 0.285 ± 0.011g
 0.7 0.341 ± 0.005e 0.216 ± 0.025h,j
 0.4 0.337 ± 0.006f 0.100 ± 0.011i,j
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Table 3
Effect of GLP-1 receptor agonist on clozapine-induced enhancement of apoptosis
and inhibition of proliferation of pancreatic islet cells. Data were expressed as the
percentage of positive islet nuclei. a,d,ep < 0.05, b,c,f,gp < 0.01 when the two indicated
means were analyzed using the unpaired Student t-test.
Clozapine GLP-1RA PIC (g) 2 weeks (n = 3) 16 weeks (n = 3)
Ki67 (%) TUNEL (%) Ki67 (%) TUNEL (%)
A − − 8.5 ± 0.8a,b 9 ± 4d 0f 9 ± 3 0
B  − + 10.5 ± 0.6a 12 ± 5 0 10 ± 4 0B 12 − + 5.55 ± 0.54 12.8 ±
C 12 + − 5.03 ± 0.31b 11.7 ±
D 12 + + 5.45 ± 0.35c 13.2 ±
.6. The apoptotic effect of clozapine on an insulin-secreting cell
ine
RINm5F cells were cultured in RPMI-1640 medium contain-
ng 100 mg/dL glucose and clozapine at concentrations of 0, 1,
0 and 25 M.  At 16 h following cultivation, the cells were har-
ested and assayed for apoptosis by ﬂow cytometry based on
he binding of PE-annexin V and 7-amino-actinomycin (7-AAD)
sing an apoptosis detection kit according to the manufacturer’s
nstructions (BD Biosciences, San Jose, CA, USA). The results were
xpressed as the percentage of PE-annexin V-negative and 7-AAD-
egative cells (viable, no apoptosis), PE-annexin V-positive but
-AAD-negative cells (early apoptosis), and PE-annexin V-positive
nd 7-AAD-positive cells (late apoptosis, dead). Data are expressed
s mean ± standard error.
.7. Histology of pancreatic islet beta cells
Mice from each group were randomly selected and their pan-
reases removed for histological examination at 2 weeks and 4
onths after sacriﬁce. The apoptotic and proliferative nuclei of
slet cells of parafﬁn-embedded pancreatic sections were detected
sing a TUNEL Apoptosis Detection Kit (GenScrip, Piscataway, NJ,
SA), and immunohistochemical analysis was performed using an
nti-Ki67 antibody (ab15580, Abcam Inc., Cambridge, MA,  USA). For
ach mouse, approximately 2000 nuclei of pancreatic islet sections
ere counted and the results were expressed as the percentage of
ositive nuclei.
.8. Pancreatic insulin content
All mice in each group were sacriﬁced at the end of 4 months,
nd the pancreases were removed and the insulin content (PIC)
etermined using an acid-ethanol extraction and insulin kit (# RI-
3k, LINCO Research, Inc., St. Charles, MO,  USA).
.9. Statistics
Data were expressed as means ± standard error. Statistical dif-
erences between means were analyzed using paired or unpaired
tudent’s t-tests or one-way ANOVA as appropriate. A p value of
ess than 0.05 was considered to be statistically signiﬁcant.
. ResultsAn acute effect of clozapine on glucose derangement was
eﬂected by a rapid and signiﬁcant increase in glucose concen-
ration after administration (Table 1, BG, group A vs. C, 0 ± 4C  + − 5.1 ± 0.3b,c 2 ± 1d,e 5 ± 2f,g 7 ± 2 0
D  + + 7.5 ± 0.8c 8 ± 3e 0g 9 ± 3 0
vs. 25 ± 3 mg/dL, p < 0.001; Fig. 1A and C). The administration of
exenatide not only rapidly suppressed the blood glucose level
(Table 1, group A vs. B, 0 ± 4 vs. −40 ± 2 mg/dL, p < 0.001; Fig. 1B)
but also effectively reversed the clozapine-induced acute eleva-
tion of blood glucose concentration (Table 1, group C vs. D, 25 ± 3
vs. −39 ± 2 mg/dL, p < 0.001; Fig. 1D). There was no signiﬁcant
difference in mean average non-fasting BG level over the whole
experimental period among the four groups (Table 1, p > 0.05). In
addition, there was no signiﬁcant difference in the function of islet
beta cells as evaluated by IPGTT at the 14th week among the four
groups (Table 1, IPGTT, one-way ANOVA, p > 0.05).
The mean basal body weights were 27.2 ± 0.5, 27.0 ± 0.6,
26.9 ± 0.5 and 27.1 ± 0.5 g in groups A–D, respectively (one-way
ANOVA, p > 0.05). At the end of 4 months, the control mice had
gained signiﬁcantly more body weight than the mice that were
treated with clozapine and/or exenatide (Table 2, BW,  groups
A vs. B, A vs. C, and A vs. D, p < 0.05). The administration of exe-
natide did not affect the clozapine-associated lower gain in body
weight or lean mass, but further reduced the peri-renal fat pad
mass (Table 2, peri-renal fat pad, group C vs. D, 0.216 ± 0.025 vs.
0.100 ± 0.011 g, p < 0.05). The amount of chow intake did not signif-
icantly differ among the four groups at the 2nd and 14th weeks (2nd
week, A: 14.4 ± 0.4, B: 13.8 ± 0.6, C: 14.0 ± 0.8, D: 13.6 ± 0.9 g/kg
body-weight/day, p > 0.05; 14th week, A: 12.4 ± 0.6, B: 12.8 ± 0.7, C:
11.7 ± 0.7, D: 13.2 ± 0.4 g/kg body-weight/day, p > 0.05).
Compared with the control mice, the administration of clozap-
ine resulted in a signiﬁcant reduction in PIC at the end of 4 months
(Table 3, PIC, group A vs. C, p < 0.01). The mice treated with exe-
natide had a higher PIC than the control mice (Table 3, PIC, group A
vs. B, p < 0.05), and exenatide treatment also restored the clozapine-
associated reduction in PIC (Table 3, PIC, group C vs. D, p < 0.01). The
immunohistochemical analysis of the pancreatic islet cells revealed
that the administration of clozapine resulted in an increase in apo-
ptosis and a decrease in proliferation markers, and this occurred as
early as 2 weeks after the start of the experiment but it attenuated
at 4 months of the experiment (Table 3 and Figs. 2 and 3).
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Table 4
Effect of clozapine on serum level of chemokines. a,bp < 0.05 when the two indicated means were analyzed using the unpaired Student t-test.
Gr n Clozapine GLP-1RA RANTES (pg/mL) GMCSF (pg/mL) MCP-1 (pg/mL) MCP-3 (pg/mL) MIP-1 (pg/mL) MIP-1(pg/mL)
A 12 − − 696 ± 54 8.9 ± 4.0 564 ± 326 440 ± 146a 4.8 ± 3.5 2.8 ± 2.6
B  12 − + 573 ± 49 9.8 ± 5.4 
C  12 + − 778 ± 42 9.8 ± 4.4 
D  12 + + 689 ± 59 10.0 ± 6.4 
Table 5
Effect of clozapine on the apoptosis of RINm5F cells. ap < 0.05, bp < 0.005, and
cp < 0.0001 when the indicated early, late and total apoptosis of each condition was
compared to that of the control condition (0 M).
Clozapine n Early apoptosis (%) Late apoptosis (%) Total apoptosis (%)
0 M 6 3.6 ± 0.3 2.0 ± 0.1 5.5 ± 0.3
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c1  M 6 4.7 ± 0.2 2.1 ± 0.2 6.8 ± 0.3
10 M 6 6.7 ± 0.1c 3.4 ± 0.2c 10.0 ± 0.1c
25 M 6 8.6 ± 0.2c 3.8 ± 0.3c 12.3 ± 0.4c
At the end of 14 weeks, the basal serum glucagon concentra-
ions in the mice in groups A–D were 15.3 ± 2.0 (n = 12), 13.0 ± 1.8
n = 12), 12.4 ± 2.1 (n = 12) and 13.9 ± 1.0 (n = 12) ng/mL, respec-
ively (p > 0.05 by one-way ANOVA). Two hours after administering
lozapine, the serum glucagon levels were 15.7 ± 2.3 (n = 12) and
5.6 ± 1.6 (n = 12) ng/mL (p > 0.05) in the mice in groups C and D,
espectively. The basal serum level of MCP-3 in the mice treated
ith clozapine was signiﬁcantly reduced, and it was totally restored
y the co-administration of exenatide (Table 4, MCP-3, groups A vs.
 and C vs. D, p < 0.05). Other basal serum chemokines including
ANTES, GM-CSF, MCP-1, MIP-1 and MIP-1 were not signiﬁ-
antly different among the four groups (Table 4).
In RINm5F cell in-vitro cultivation study, the percentage of early
nd total apoptosis increased signiﬁcantly after incubation with
 M clozapine for 16 h (Table 5). At a concentration of 10 M cloza-
ine, the late apoptosis of RINm5F cell also signiﬁcantly increased
Table 5). Both clozapine-associated early and late apoptosis of
INm5F cell are dose-dependent (Table 5).
. Discussion and conclusions
Our results suggest that clozapine treatment resulted in a sig-
iﬁcant increase in apoptosis and inhibition of the proliferation of
ancreatic islet cells, and that this occurred as early as 2 weeks after
ts administration. The anti-proliferative effect of clozapine on islet
ells was attenuated at four months of treatment. Although the
on-fasting random blood glucose level of the mice treated with
lozapine did not increase signiﬁcantly during the experimental
eriod, the adverse effect of clozapine on islet beta cells was  con-
rmed by a 40% reduction in PIC in the mice treated with clozapine
or 4 months. Using a rat beta cell line, RINm5F, we found that cloza-
ine directly increased the apoptosis of insulin-secreting cells in
 dose-dependent manner. It has been reported that preservation
f more than one-tenth of the mass of beta cells in a healthy pan-
reas is adequate to maintain normal glucose metabolism [13]. This
ay  explain, at least partly, why the random non-fasting blood glu-
ose levels in the mice treated with clozapine in this study did not
ncrease signiﬁcantly. Since the AUC of IPGTT did not signiﬁcantly
iffer between the mice treated and not treated with clozapine, the
lucose-stimulated insulin secretion of pancreatic islet beta cells
id not seem to be disrupted by the long-term administration of
lozapine.
A previous rat study reported that administration of a single
ose of clozapine resulted in suppression of the serum level of
LP-1 and increase in glucagon level, thereby resulting in acute
erangement of glucose metabolism [8]. Mechanisms such as the
lozapine-induced activation of hepatic phosphorylase and G6Pase429 ± 142 258 ± 62 12.9 ± 7.3 22.3 ± 9.4
479 ± 117 189 ± 33a,b 13.2 ± 5.3 81.7 ± 36.3
469 ± 187 430 ± 64b 20.4 ± 12.9 10.9 ± 7.0
have been proposed to be involved in atypical antipsychotic-
associated increases in the hepatic glucose output [14]. It also
has been reported that clozapine is a potent acetylcholine mus-
carinic M3  receptor (M3R) antagonist and both pancreatic and
hypothalamic and brainstem M3Rs regulate the insulin secretion
and alter glucometabolic status of the body [15]. Another recent
study reported that acute treatment with olanzapine caused glu-
cose intolerance through the activation of hypothalamic adenosine
5′-monophosphate-activated protein kinase (AMPK) [16]. Clozap-
ine has also been reported to signiﬁcantly induce the production
of proinﬂammatory cytokines in cultured insulin responsive cells,
and by doing this clozapine may  interfere in insulin action and
result in peripheral insulin resistance [17]. Our results reveal that
the long-term administration of clozapine did not increase the lev-
els of proinﬂammatory chemokines. Only a signiﬁcant decrease in
MCP-3 was found in the mice treated with clozapine, which is com-
patible with a previous in-vitro cell culture study which found that
clozapine reduced PMN  chemotaxis [18]. Our results suggest that
this mechanism of clozapine-associated derangements of glucose
metabolism is multifactorial.
In this study, we  did not ﬁnd a signiﬁcant difference in the serum
level of glucagon between baseline and 2 h after the administra-
tion clozapine in the mice treated with clozapine for 4 months.
Meanwhile, the clozapine-associated increase in glucose variability
was larger in the ﬁrst two months but it was getting smaller in the
4th month of treatment. Moreover, the clozapine-associated anti-
proliferative effects on islet cells were also attenuated at the end of
4 months of treatment. In a rodent phencyclidine (PCP)-induced
hyperlocomotion model, adult response to clozapine treatment
is attenuated by adolescent clozapine exposure [19]. Moreover,
repeated administration of clozapine has been reported to induce
tolerance to clozapine-associated disruption of avoidance response
in rodents [20]. The mechanism that causes clozapine tolerance in
disruptive avoidance response and PCP-induced hyperlocomotion
is thought to be related with serotonin 5-HT 2A/2C expressed in
medial prefrontal cortex or nucleus accumbens shell [21]. How-
ever, the mechanism by which the mice were spared the long-term
effect of clozapine-associated glucagon dysregulation and the anti-
proliferative property on islet beta cells in this study is not clear.
Our results also revealed that the mice treated with clozapine
had less body weight gain, less gastrocnemius muscle mass, and
less peri-renal fat pad mass compared to the control mice. In the
mice treated with clozapine, the body weight loss did not result
from a loss of appetite, because the daily chow intake per kilogram
body weight did not differ among the four groups. The mechanism
for the lower increase in body weight, skeletal muscle and visceral
fat mass in the mice treated with clozapine is unknown. Smith et al.
reported that 10 M of clozapine, which is approximate 10 times
higher than the therapeutic concentration, resulted in a marginal
decrease in glucose uptake in 3T3L1 adipocytes in a rodent model
but did not reduce glucose uptake in soleus muscles in vitro [7].
We estimate that the serum concentration of clozapine in the mice
orally fed with 13.5 mg/kg body weight clozapine was  about 1 M,
which was not sufﬁcient to reduce blood glucose disposal through
skeletal muscles and visceral adipocytes. Therefore, the mechanism
of action for changes in the mass of skeletal muscles and visceral
fat in the mice treated with clozapine was  not likely due to a direct
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ffect of clozapine on glucose uptake in skeletal muscles and vis-
eral adipocytes in this study. Moreover, the clozapine-associated
cute increase in serum glucose level was not due to a reduction
n glucose uptake of skeletal muscles or visceral fat cells. However,
t is not clear whether clozapine-associated changes in lean mus-
le and visceral fat are also related to central AMPK and/or M3Rs
ctivities [15,16].
In conclusion, clozapine treatment resulted in acute derange-
ents in glucose metabolism, decreased proliferation and
ncreased apoptosis of pancreatic islet cells, which resulted in a
eduction in PIC. With the administration of a GLP-1 receptor
gonist, exenatide, the clozapine-associated enhancement of apo-
tosis, inhibition of islet cell proliferation and loss of pancreatic
eta cell mass were completely restored. Moreover, by the admin-
stration of exenatide, the acute increase in serum glucose level was
otally reversed in the mice treated with clozapine, and this may
xert an additional protective effect on the cardiovascular system
n schizophrenic patients, who are at high risk of major cardiovas-
ular events [22–24]. Our results provide preclinical evidence of
he pharmaceutical role of GLP-1 receptor agonists in managing
lucose dysregulation in schizophrenic patients under long-term
typical antipsychotic treatment.
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